TIPE3 and breast carcinoma: To confirm the effect of TIPE3 on AKT and NF-κB pathways in breast cancer, inhibitors CAPE (inhibitor of NF-κB) [30] and LY294002 (inhibitor of PI3K inhibitor) [31] were used in this study.